FIRE1, a leading connected medical device solutions company, today announced the successful completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure.

领先的互联医疗设备解决方案公司FIRE1今天宣布，成功完成了一轮1.2亿美元的融资，以加速公司改变数百万心力衰竭患者生活的使命。

FIRE1’s Norm™ heart failure management system offers a groundbreaking approach for patients to manage heart failure. By enabling patients to engage in physician directed self-management, Norm reduces the burden on healthcare staff, making it easier to keep patients healthier and at home. The funding will enable the company to complete a pivotal clinical trial of the Norm™ system..

FIRE1的Norm™心力衰竭管理系统为患者管理心力衰竭提供了一种开创性的方法。通过让患者参与医生指导的自我管理，Norm减轻了医护人员的负担，使患者更容易保持健康和在家中。这笔资金将使该公司能够完成Norm™系统的关键临床试验。。

The round was led by Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and existing investors Andera Partners, Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, NEA (New Enterprise Associates), Novo Holdings, and Seventure Partners..

这一轮由Polaris Partners和Elevate Medical Technologies牵头，新投资者Sands Capital和Longitude Capital以及现有投资者Andera Partners、Gilde Healthcare、Gimv、爱尔兰战略投资基金、Lightstone Ventures、Medtronic、NEA（new Enterprise Associates）、Novo Holdings和Seventure Partners加入。。

“From the beginning, our team has been driven by two core goals: creating a better way to manage heart failure by monitoring fluid volume more directly, and empowering patients with actionable data to improve their lives,” said Conor Hanley, CEO and President of FIRE1. “I am thrilled to welcome four more world-class investors to our exceptional syndicate.”.

FIRE1首席执行官兼总裁康纳·汉利（Conor Hanley）表示：“从一开始，我们的团队就受到两个核心目标的驱动：通过更直接地监测液体量来创建更好的心力衰竭管理方法，并为患者提供可行的数据以改善他们的生活。”。“我很高兴再欢迎四位世界级投资者加入我们的特殊财团。”。

In addition to the financing, FIRE1 announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) and has been accepted into the FDA’s Total Product Lifecycle Advisory Program (TAP).

除融资外，FIRE1宣布已获得美国食品和药物管理局（FDA）的突破性设备指定，并已被FDA的总产品生命周期咨询计划（TAP）接受。

The company also welcomed Ellie McGuire, Partner at Polaris Partners, and Michael Wasserman, COO at Elevage Medical Technologies, to its Board of Directors.

该公司还欢迎Polaris Partners合伙人Ellie McGuire和Elevage Medical Technologies首席运营官Michael Wasserman加入董事会。

“FIRE1 has developed a groundbreaking solution to one of healthcare’s most pressing challenges: providing scalable ways to manage the disease of chronically ill patients and prevent the need for frequent hospitalizations,” said Ms. McGuire. “The Norm™ heart failure self-management system is a first-of-its-kind innovation that empowers patients to take greater control of their health.

McGuire女士说：“FIRE1为医疗保健最紧迫的挑战之一开发了一种开创性的解决方案：提供可扩展的方法来管理慢性病患者的疾病，并防止频繁住院。”。“Norm™心力衰竭自我管理系统是此类创新中的第一个，它使患者能够更好地控制自己的健康。

We believe this represents a paradigm shift in chronic disease management.”.

我们认为这代表了慢性病管理的范式转变。”。

Mr. Wasserman added, “FIRE1’s unique approach to heart failure—a more direct measure of volume instead of relying on proxies—has generated significant excitement in the clinical community. This differentiated approach positions FIRE1 to unlock substantial market opportunities, and we are proud to support the company on this journey.”.

Wasserman先生补充道：“FIRE1治疗心力衰竭的独特方法-一种更直接的体积测量方法，而不是依赖代理，在临床界引起了极大的兴奋。这种差异化的方法使FIRE1能够打开巨大的市场机会，我们很自豪能在这一过程中支持该公司。”。

About FIRE1

关于FIRE1

Headquartered in Dublin, Ireland, FIRE1 is a connected medical device solutions company dedicated to improving outcomes for individuals suffering from chronic diseases. Its mission is to empower millions of people with heart failure to regain their normal lives. The experienced FIRE1 team collaborates with world-leading researchers, clinicians, patients, and payors to alleviate the burden of heart failure..

FIRE1总部位于爱尔兰都柏林，是一家关联医疗器械解决方案公司，致力于改善慢性病患者的预后。它的使命是让数百万心力衰竭患者恢复正常生活。经验丰富的FIRE1团队与世界领先的研究人员、临床医生、患者和付款人合作，减轻心力衰竭的负担。。

For more information, visit www.fire1foundry.com.

有关更多信息，请访问www.fire1foundry.com。

About Polaris Partners

关于Polaris Partners

Polaris Partners has a 25-plus-year history of partnering with repeat entrepreneurs and world-class innovators who are improving the way we live and work. The multibillion-dollar firm manages specialty and diversified funds in healthcare and healthcare-adjacent technology with investments across all stages.

Polaris Partners与不断改进我们生活和工作方式的重复创业者和世界级创新者合作已有25多年的历史。这家价值数十亿美元的公司管理着医疗保健和医疗保健相关技术的专业和多元化基金，并在各个阶段进行投资。

Polaris has offices in Boston, San Francisco, New York, and Singapore. Learn more at www.polarispartners.com..

Polaris在波士顿、旧金山、纽约和新加坡设有办事处。更多信息，请访问www.polarispartners.com。。

About Elevage Medical Technologies

关于Elevage Medical Technologies

Elevage Medical Technologies is a platform established by Patient Square Capital and is dedicated to supporting medical technology companies that can meaningfully improve health outcomes and quality of life for patients. Elevage provides capital along with deep technical, regulatory, and operational expertise to companies ranging from advanced clinical development to commercial acceleration stage.

Elevate Medical Technologies是由Patient Square Capital建立的一个平台，致力于支持能够有意义地改善患者健康状况和生活质量的医疗技术公司。Elevage为从高级临床开发到商业加速阶段的公司提供资金以及深入的技术、监管和运营专业知识。

Elevage supports rapidly growing, highly differentiated companies with paradigm shifting technologies and strives to help build industry leading medical technologies. To learn more about Elevage, please visit www.elevagemedical.com..

Elevage支持快速发展、高度分化的公司，采用范式转换技术，并努力帮助建立行业领先的医疗技术。要了解更多有关Elevage的信息，请访问www.elevagemedical.com。。

Contacts

联系人

Josie Zohny

乔西·佐尼

[email protected]

[受电子邮件保护]

877-887-7611

877-887-7611

Source: businesswire.com

来源：businesslive.com